BIMI INTERNATIONAL MEDICAL I (BIMI) Fundamental Analysis & Valuation
NASDAQ:BIMI • US05552Q3011
Current stock price
0.31 USD
-0.17 (-35.42%)
At close:
0.3115 USD
+0 (+0.48%)
After Hours:
This BIMI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BIMI Profitability Analysis
1.1 Basic Checks
- In the past year BIMI has reported negative net income.
- BIMI had a negative operating cash flow in the past year.
1.2 Ratios
- BIMI's Return On Assets of -30.51% is on the low side compared to the rest of the industry. BIMI is outperformed by 83.48% of its industry peers.
- BIMI has a Return On Equity of -122.77%. This is in the lower half of the industry: BIMI underperforms 77.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.51% | ||
| ROE | -122.77% | ||
| ROIC | N/A |
ROA(3y)-54.49%
ROA(5y)-50.22%
ROE(3y)-292.5%
ROE(5y)-218.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of BIMI (41.01%) is better than 69.57% of its industry peers.
- BIMI's Gross Margin has improved in the last couple of years.
- BIMI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y8.8%
2. BIMI Health Analysis
2.1 Basic Checks
- BIMI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for BIMI has been increased compared to 1 year ago.
- The debt/assets ratio for BIMI has been reduced compared to a year ago.
2.2 Solvency
- BIMI has an Altman-Z score of -3.03. This is a bad value and indicates that BIMI is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of BIMI (-3.03) is worse than 86.09% of its industry peers.
- A Debt/Equity ratio of 0.13 indicates that BIMI is not too dependend on debt financing.
- With a decent Debt to Equity ratio value of 0.13, BIMI is doing good in the industry, outperforming 73.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.03 |
ROIC/WACCN/A
WACC5.72%
2.3 Liquidity
- A Current Ratio of 1.21 indicates that BIMI should not have too much problems paying its short term obligations.
- With a Current ratio value of 1.21, BIMI perfoms like the industry average, outperforming 41.74% of the companies in the same industry.
- BIMI has a Quick Ratio of 1.21. This is a bad value and indicates that BIMI is not financially healthy enough and could expect problems in meeting its short term obligations.
- BIMI's Quick ratio of 0.86 is on the low side compared to the rest of the industry. BIMI is outperformed by 69.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.86 |
3. BIMI Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 96.66% over the past year.
- Looking at the last year, BIMI shows a quite strong growth in Revenue. The Revenue has grown by 14.31% in the last year.
- Measured over the past years, BIMI shows a small growth in Revenue. The Revenue has been growing by 6.81% on average per year.
EPS 1Y (TTM)96.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.72%
Revenue 1Y (TTM)14.31%
Revenue growth 3Y319.71%
Revenue growth 5Y6.81%
Sales Q2Q%-65.48%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. BIMI Valuation Analysis
4.1 Price/Earnings Ratio
- BIMI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. BIMI Dividend Analysis
5.1 Amount
- No dividends for BIMI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIMI Fundamentals: All Metrics, Ratios and Statistics
0.31
-0.17 (-35.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)06-24 2024-06-24/amc
Earnings (Next)11-25 2024-11-25
Inst Owners0.16%
Inst Owner Change0%
Ins Owners210.74%
Ins Owner Change0%
Market Cap2.07M
Revenue(TTM)10.25M
Net Income(TTM)-10.69M
Analysts0
Price TargetN/A
Short Float %4.63%
Short Ratio0.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.5 | ||
| P/tB | 0.7 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.58
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.73
BVpS0.62
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.51% | ||
| ROE | -122.77% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.01% | ||
| FCFM | N/A |
ROA(3y)-54.49%
ROA(5y)-50.22%
ROE(3y)-292.5%
ROE(5y)-218.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y8.8%
F-Score6
Asset Turnover0.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.86 | ||
| Altman-Z | -3.03 |
F-Score6
WACC5.72%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.72%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.31%
Revenue growth 3Y319.71%
Revenue growth 5Y6.81%
Sales Q2Q%-65.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y75.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.35%
OCF growth 3YN/A
OCF growth 5YN/A
BIMI INTERNATIONAL MEDICAL I / BIMI Fundamental Analysis FAQ
What is the ChartMill fundamental rating of BIMI INTERNATIONAL MEDICAL I (BIMI) stock?
ChartMill assigns a fundamental rating of 1 / 10 to BIMI.
Can you provide the valuation status for BIMI INTERNATIONAL MEDICAL I?
ChartMill assigns a valuation rating of 0 / 10 to BIMI INTERNATIONAL MEDICAL I (BIMI). This can be considered as Overvalued.
How profitable is BIMI INTERNATIONAL MEDICAL I (BIMI) stock?
BIMI INTERNATIONAL MEDICAL I (BIMI) has a profitability rating of 1 / 10.
How financially healthy is BIMI INTERNATIONAL MEDICAL I?
The financial health rating of BIMI INTERNATIONAL MEDICAL I (BIMI) is 2 / 10.